4 years ago
Amphista Therapeutics Secures $53 Million in Series B Funding to Advance Targeted Protein Degradation Platform
Amphista Therapeutics, a UK-based leader in targeted protein degradation (TPD) approaches, has secured $53 million in Series B funding
The round was co-led by Forbion and Gilde Healthcare with participation from Novartis Venture Fund, Eli Lilly and Company, BioMotiv, and Advent Life Sciences
Amphista intends to use the funds to accelerate its pipeline of TPD-based medicines to the clinic and expand its platform, targeting challenging diseases like cancer
The company's innovative approach involves harnessing the body's natural processes to selectively remove disease-causing proteins.
ProblemHealthcare
"Developing new cancer treatments is often hampered by the lack of effective and safe drugs that can target specific proteins involved in disease development."
Solution
"Amphista Therapeutics is developing a new type of medicine called 'Amphistas' which use the body's natural processes to selectively degrade and remove disease-causing proteins. This approach could lead to more effective and safer cancer treatments."